JPWO2020140084A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020140084A5 JPWO2020140084A5 JP2021537082A JP2021537082A JPWO2020140084A5 JP WO2020140084 A5 JPWO2020140084 A5 JP WO2020140084A5 JP 2021537082 A JP2021537082 A JP 2021537082A JP 2021537082 A JP2021537082 A JP 2021537082A JP WO2020140084 A5 JPWO2020140084 A5 JP WO2020140084A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr3
- cdr2
- cdr1
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000025417 antigen binding proteins Human genes 0.000 claims description 44
- 108091000829 antigen binding proteins Proteins 0.000 claims description 44
- 101700054183 CTLA4 Proteins 0.000 claims description 9
- 102100005310 CTLA4 Human genes 0.000 claims description 9
- 229920000023 polynucleotide Polymers 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 210000004027 cells Anatomy 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 4
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims description 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 3
- 206010060945 Bacterial infection Diseases 0.000 claims description 3
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 3
- 229940121652 CTLA-4 inhibitors Drugs 0.000 claims description 3
- 102100006047 TIGIT Human genes 0.000 claims description 3
- 101700052319 TIGIT Proteins 0.000 claims description 3
- 206010047461 Viral infection Diseases 0.000 claims description 3
- 208000001756 Virus Disease Diseases 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000003308 immunostimulating Effects 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 101000231958 CTLA4 Proteins 0.000 claims description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 2
- 102000023583 human CTLA4 protein Human genes 0.000 claims description 2
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 2
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 2
Description
本開示の別の態様は、疾患を処置する方法であって、それを必要とする対象に、本明細書で開示されるABPのまたは本明細書で開示される医薬組成物の有効量を投与するステップを含む方法を提供する。一部の実施形態では、疾患は、がん、AIDS、アルツハイマー病およびウイルスまたは細菌感染症からなる群から選択される。一部の実施形態では、方法は、1つまたは複数の追加の治療剤を対象に投与するステップをさらに含む。一部の実施形態では、追加の治療剤は、CTLA-4阻害剤、TIGIT阻害剤、化学療法剤、免疫刺激剤、放射線、サイトカイン、サイトカインをコードするポリヌクレオチド、およびこれらの組合せから選択される。
特定の実施形態では、例えば以下の項目が提供される。
(項目1)
ヒト細胞傷害性Tリンパ球関連タンパク質4(CTLA-4)に特異的に結合する単離された抗原結合タンパク質(ABP)であって、
(a)配列番号3001~3028から選択される配列を有するCDR3-L、および配列番号6001~6028から選択される配列を有するCDR3-H;または
(b)配列番号9984~10479から選択される配列を有するCDR3-L、および配列番号11472~11967から選択される配列を有するCDR3-H;または
(c)ATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのCD3-Lの配列を有するCDR3-L、およびATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのCD3-Lの配列を有するCDR3-L
を含む、単離された抗原結合タンパク質(ABP)。
(項目2)
前記CDR3-Lおよび前記CDR3-Hが、同族対である、項目1に記載のABP。
(項目3)
(a)配列番号1001~1028から選択される配列を有するCDR1-L;および配列番号2001~2028から選択される配列を有するCDR2-L;および配列番号4001~4028から選択される配列を有するCDR1-H;および配列番号5001~5028から選択される配列を有するCDR2-H;または
(b)配列番号8992~9487から選択される配列を有するCDR1-L;および配列番号9488~9983から選択される配列を有するCDR2-L;および配列番号10480~10975から選択される配列を有するCDR1-H;および配列番号10976~11471から選択される配列を有するCDR2-H;または
(c)ATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのCDR1-Lから選択される配列を有するCDR1-L;およびATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのCDR2-Lから選択される配列を有するCDR2-L;およびATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのCDR1-Hから選択される配列を有するCDR1-H;およびATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのCDR2-Hから選択される配列を有するCDR2-H
を含む、項目1に記載のABP。
(項目4)
CDR1-L、CDR2-L、CDR3-L、CDR1-H、CDR2-HおよびCDR3-Hを含み、
前記CDR1-Lが、配列番号1001からなり、前記CDR2-Lが、配列番号2001からなり、前記CDR3-Lが、配列番号3001からなり、前記CDR1-Hが、配列番号4001からなり、前記CDR2-Hが、配列番号5001からなり、前記CDR3-Hが、配列番号6001からなるか;または
前記CDR1-Lが、配列番号1002からなり、CDR2-Lが、配列番号2002からなり、前記CDR3-Lが、配列番号3002からなり、前記CDR1-Hが、配列番号4002からなり、前記CDR2-Hが、配列番号5002からなり、前記CDR3-Hが、配列番号6002からなるか;または
前記CDR1-Lが、配列番号1003からなり、前記CDR2-Lが、配列番号2003からなり、前記CDR3-Lが、配列番号3003からなり、前記CDR1-Hが、配列番号4003からなり、前記CDR2-Hが、配列番号5003からなり、前記CDR3-Hが、配列番号6003からなるか;または
前記CDR1-Lが、配列番号1004からなり、前記CDR2-Lが、配列番号2004からなり、前記CDR3-Lが、配列番号3004からなり、前記CDR1-Hが、配列番号4004からなり、前記CDR2-Hが、配列番号5004からなり、前記CDR3-Hが、配列番号6004からなるか;または
前記CDR1-Lが、配列番号1005からなり、前記CDR2-Lが、配列番号2005からなり、前記CDR3-Lが、配列番号3005からなり、前記CDR1-Hが、配列番号4005からなり、前記CDR2-Hが、配列番号5005からなり、前記CDR3-Hが、配列番号6005からなるか;または
前記CDR1-Lが、配列番号1006からなり、前記CDR2-Lが、配列番号2006からなり、前記CDR3-Lが、配列番号3006からなり、前記CDR1-Hが、配列番号4006からなり、前記CDR2-Hが、配列番号5006からなり、前記CDR3-Hが、配列番号6006からなるか;または
前記CDR1-Lが、配列番号1007からなり、前記CDR2-Lが、配列番号2007からなり、前記CDR3-Lが、配列番号3007からなり、前記CDR1-Hが、配列番号4007からなり、前記CDR2-Hが、配列番号5007からなり、前記CDR3-Hが、配列番号6007からなるか;または
前記CDR1-Lが、配列番号1008からなり、前記CDR2-Lが、配列番号2008からなり、前記CDR3-Lが、配列番号3008からなり、前記CDR1-Hが、配列番号4008からなり、前記CDR2-Hが、配列番号5008からなり、前記CDR3-Hが、配列番号6008からなるか;または
前記CDR1-Lが、配列番号1009からなり、前記CDR2-Lが、配列番号2009からなり、前記CDR3-Lが、配列番号3009からなり、前記CDR1-Hが、配列番号4009からなり、前記CDR2-Hが、配列番号5009からなり、前記CDR3-Hが、配列番号6009からなるか;または
前記CDR1-Lが、配列番号1010からなり、前記CDR2-Lが、配列番号2010からなり、前記CDR3-Lが、配列番号3010からなり、前記CDR1-Hが、配列番号4010からなり、前記CDR2-Hが、配列番号5010からなり、前記CDR3-Hが、配列番号6010からなるか;または
前記CDR1-Lが、配列番号1011からなり、前記CDR2-Lが、配列番号2011からなり、前記CDR3-Lが、配列番号3011からなり、前記CDR1-Hが、配列番号4011からなり、前記CDR2-Hが、配列番号5011からなり、前記CDR3-Hが、配列番号6011からなるか;または
前記CDR1-Lが、配列番号1012からなり、前記CDR2-Lが、配列番号2012からなり、前記CDR3-Lが、配列番号3012からなり、前記CDR1-Hが、配列番号4012からなり、前記CDR2-Hが、配列番号5012からなり、前記CDR3-Hが、配列番号6012からなるか;または
前記CDR1-Lが、配列番号1013からなり、前記CDR2-Lが、配列番号2013からなり、前記CDR3-Lが、配列番号3013からなり、前記CDR1-Hが、配列番号4013からなり、前記CDR2-Hが、配列番号5013からなり、前記CDR3-Hが、配列番号6013からなるか;または
前記CDR1-Lが、配列番号1014からなり、前記CDR2-Lが、配列番号2014からなり、前記CDR3-Lが、配列番号3014からなり、前記CDR1-Hが、配列番号4014からなり、前記CDR2-Hが、配列番号5014からなり、前記CDR3-Hが、配列番号6014からなるか;または
前記CDR1-Lが、配列番号1015からなり、前記CDR2-Lが、配列番号2015からなり、前記CDR3-Lが、配列番号3015からなり、前記CDR1-Hが、配列番号4015からなり、前記CDR2-Hが、配列番号5015からなり、前記CDR3-Hが、配列番号6015からなるか;または
前記CDR1-Lが、配列番号1016からなり、前記CDR2-Lが、配列番号2016からなり、前記CDR3-Lが、配列番号3016からなり、前記CDR1-Hが、配列番号4016からなり、前記CDR2-Hが、配列番号5016からなり、前記CDR3-Hが、配列番号6016からなるか;または
前記CDR1-Lが、配列番号1017からなり、前記CDR2-Lが、配列番号2017からなり、前記CDR3-Lが、配列番号3017からなり、前記CDR1-Hが、配列番号4017からなり、前記CDR2-Hが、配列番号5017からなり、前記CDR3-Hが、配列番号6017からなるか;または
前記CDR1-Lが、配列番号1018からなり、前記CDR2-Lが、配列番号2018からなり、前記CDR3-Lが、配列番号3018からなり、前記CDR1-Hが、配列番号4018からなり、前記CDR2-Hが、配列番号5018からなり、前記CDR3-Hが、配列番号6018からなるか;または
前記CDR1-Lが、配列番号1019からなり、前記CDR2-Lが、配列番号2019からなり、前記CDR3-Lが、配列番号3019からなり、前記CDR1-Hが、配列番号4019からなり、前記CDR2-Hが、配列番号5019からなり、前記CDR3-Hが、配列番号6019からなるか;または
前記CDR1-Lが、配列番号1020からなり、前記CDR2-Lが、配列番号2020からなり、前記CDR3-Lが、配列番号3020からなり、前記CDR1-Hが、配列番号4020からなり、前記CDR2-Hが、配列番号5020からなり、前記CDR3-Hが、配列番号6020からなるか;または
前記CDR1-Lが、配列番号1021からなり、前記CDR2-Lが、配列番号2021からなり、前記CDR3-Lが、配列番号3021からなり、前記CDR1-Hが、配列番号4021からなり、前記CDR2-Hが、配列番号5021からなり、前記CDR3-Hが、配列番号6021からなるか;または
前記CDR1-Lが、配列番号1022からなり、前記CDR2-Lが、配列番号2022からなり、前記CDR3-Lが、配列番号3022からなり、前記CDR1-Hが、配列番号4022からなり、前記CDR2-Hが、配列番号5022からなり、前記CDR3-Hが、配列番号6022からなるか;または
前記CDR1-Lが、配列番号1023からなり、前記CDR2-Lが、配列番号2023からなり、前記CDR3-Lが、配列番号3023からなり、前記CDR1-Hが、配列番号4023からなり、前記CDR2-Hが、配列番号5023からなり、前記CDR3-Hが、配列番号6023からなるか;または
前記CDR1-Lが、配列番号1024からなり、前記CDR2-Lが、配列番号2024からなり、前記CDR3-Lが、配列番号3024からなり、前記CDR1-Hが、配列番号4024からなり、前記CDR2-Hが、配列番号5024からなり、前記CDR3-Hが、配列番号6024からなるか;または
前記CDR1-Lが、配列番号1025からなり、前記CDR2-Lが、配列番号2025からなり、前記CDR3-Lが、配列番号3025からなり、前記CDR1-Hが、配列番号4025からなり、前記CDR2-Hが、配列番号5025からなり、前記CDR3-Hが、配列番号6025からなるか;または
前記CDR1-Lが、配列番号1026からなり、前記CDR2-Lが、配列番号2026からなり、前記CDR3-Lが、配列番号3026からなり、前記CDR1-Hが、配列番号4026からなり、前記CDR2-Hが、配列番号5026からなり、前記CDR3-Hが、配列番号6026からなるか;または
前記CDR1-Lが、配列番号1027からなり、前記CDR2-Lが、配列番号2027からなり、前記CDR3-Lが、配列番号3027からなり、前記CDR1-Hが、配列番号4027からなり、前記CDR2-Hが、配列番号5027からなり、前記CDR3-Hが、配列番号6027からなるか;または
前記CDR1-Lが、配列番号1028からなり、前記CDR2-Lが、配列番号2028からなり、前記CDR3-Lが、配列番号3028からなり、前記CDR1-Hが、配列番号4028からなり、前記CDR2-Hが、配列番号5028からなり、前記CDR3-Hが、配列番号6028からなる、項目1に記載のABP。
(項目5)
配列番号1~28から選択される配列と少なくとも97%同一の配列を含む可変軽鎖(V
L
)、および配列番号101~128から選択される配列と少なくとも97%同一の配列を含む可変重鎖(V
H
);または
配列番号8000~8495から選択される配列と少なくとも97%同一の配列を含む可変軽鎖(V
L
)、および配列番号8496~8991から選択される配列と少なくとも97%同一の配列を含む可変重鎖(V
H
);または
ATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのV
L
配列と少なくとも97%同一の配列を含む可変軽鎖(V
L
)、およびATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのV
H
配列と少なくとも97%同一の配列を含む可変重鎖(V
H
)
を含む、項目1に記載のABP。
(項目6)
前記V
L
および前記V
H
が、同族対である、項目5に記載のABP。
(項目7)
配列番号1~28から選択される配列を含む可変軽鎖(V
L
)、および配列番号101~128から選択される配列を含む可変重鎖(V
H
);または
配列番号8000~8495から選択される配列を含む可変軽鎖(V
L
)、および配列番号8496~8991から選択される配列を含む可変重鎖(V
H
);または
ATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのV
L
配列を含む可変軽鎖(V
L
)、およびATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのV
H
配列を含む可変重鎖(V
H
)
を含む、項目1に記載のABP。
(項目8)
前記V
L
および前記V
H
が、同族対である、項目7に記載のABP。
(項目9)
scFvまたは全長モノクローナル抗体を含む、項目1から8のいずれかに記載のABP。
(項目10)
免疫グロブリン定常領域を含む、項目1から8のいずれかに記載のABP。
(項目11)
表面プラズモン共鳴により測定して、500nM未満のK
D
でヒトCTLA-4に結合する、前記項目のいずれかに記載のABP。
(項目12)
表面プラズモン共鳴により測定して、200nM未満のK
D
でヒトCTLA-4に結合する、項目11に記載のABP。
(項目13)
表面プラズモン共鳴により測定して、25nM未満のK
D
でヒトCTLA-4に結合する、項目12に記載のABP。
(項目14)
25nM未満のK
D
で細胞表面上のヒトCTLA-4と結合する、項目1から13のいずれかに記載のABP。
(項目15)
項目1から14のいずれかに記載のABPと賦形剤とを含む、医薬組成物。
(項目16)
疾患を処置する方法であって、
それを必要とする対象に、項目1から14のいずれかに記載のABPまたは項目15に記載の医薬組成物の有効量を投与するステップ
を含む、方法。
(項目17)
前記疾患が、がん、AIDS、アルツハイマー病およびウイルスまたは細菌感染症からなる群から選択される、項目16に記載の方法。
(項目18)
前記対象に1つまたは複数の追加の治療剤を投与するステップをさらに含む、項目16から17のいずれかに記載の方法。
(項目19)
前記追加の治療剤が、CTLA-4阻害剤、TIGIT阻害剤、化学療法剤、免疫刺激剤、放射線、サイトカイン、サイトカインをコードするポリヌクレオチド、およびこれらの組合せから選択される、項目18に記載の方法。
(項目20)
項目1から10のいずれかに記載のABPをコードする、単離されたポリヌクレオチド。
(項目21)
項目20に記載の単離されたポリヌクレオチドを含むベクター。
(項目22)
項目20に記載の単離されたポリヌクレオチドまたは項目21に記載のベクターを含む宿主細胞。
(項目23)
ヒトCTLA-4に特異的に結合する単離された抗原結合タンパク質(ABP)を産生する方法であって、
項目22に記載の宿主細胞において前記ABPを発現させること、および前記ABPを単離すること
を含む方法。
6.図面の簡単な説明
Another aspect of the present disclosure is a method of treating a disease comprising administering to a subject in need thereof an effective amount of an ABP disclosed herein or of a pharmaceutical composition disclosed herein A method is provided that includes the step of: In some embodiments the disease is selected from the group consisting of cancer, AIDS, Alzheimer's disease and viral or bacterial infections. In some embodiments, the method further comprises administering one or more additional therapeutic agents to the subject. In some embodiments, the additional therapeutic agent is selected from CTLA-4 inhibitors, TIGIT inhibitors, chemotherapeutic agents, immunostimulatory agents, radiation, cytokines, polynucleotides encoding cytokines, and combinations thereof .
In certain embodiments, for example, the following items are provided.
(Item 1)
An isolated antigen binding protein (ABP) that specifically binds to human cytotoxic T lymphocyte-associated protein 4 (CTLA-4), comprising:
(a) CDR3-L having a sequence selected from SEQ ID NOs:3001-3028 and CDR3-H having a sequence selected from SEQ ID NOs:6001-6028; or
(b) CDR3-L having a sequence selected from SEQ ID NOs:9984-10479 and CDR3-H having a sequence selected from SEQ ID NOs:11472-11967; or
(c) a CDR3-L having the sequence of the CD3-L of any one of the clones in the library deposited under ATCC Accession No. PTA-125512 and a library deposited under ATCC Accession No. PTA-125512; CDR3-L with the sequence of CD3-L of any one of the clones in the rally
An isolated antigen binding protein (ABP) comprising:
(Item 2)
The ABP of item 1, wherein said CDR3-L and said CDR3-H are a cognate pair.
(Item 3)
(a) CDR1-L having a sequence selected from SEQ ID NOs: 1001-1028; and CDR2-L having a sequence selected from SEQ ID NOs: 2001-2028; and CDR1 having a sequence selected from SEQ ID NOs: 4001-4028 -H; and CDR2-H having a sequence selected from SEQ ID NOS: 5001-5028; or
(b) CDR1-L having a sequence selected from SEQ ID NOs:8992-9487; and CDR2-L having a sequence selected from SEQ ID NOs:9488-9983; and CDR1 having a sequence selected from SEQ ID NOs:10480-10975 -H; and CDR2-H having a sequence selected from SEQ ID NOS: 10976-11471; or
(c) a CDR1-L having a sequence selected from the CDR1-L of any one of the clones in the library deposited under ATCC Accession No. PTA-125512; and deposited under ATCC Accession No. PTA-125512. CDR2-L having a sequence selected from the CDR2-L of any one of the clones in the library filed; and CDR1 of any one of the clones in the library deposited under ATCC Accession No. PTA-125512. -H; and CDR2-H with a sequence selected from the CDR2-H of any one of the clones in the library deposited under ATCC Accession No. PTA-125512.
The ABP of item 1, comprising
(Item 4)
including CDR1-L, CDR2-L, CDR3-L, CDR1-H, CDR2-H and CDR3-H;
The CDR1-L consists of SEQ ID NO: 1001, the CDR2-L consists of SEQ ID NO: 2001, the CDR3-L consists of SEQ ID NO: 3001, the CDR1-H consists of SEQ ID NO: 4001, and the CDR2 -H consists of SEQ ID NO:5001 and said CDR3-H consists of SEQ ID NO:6001; or
The CDR1-L consists of SEQ ID NO: 1002, the CDR2-L consists of SEQ ID NO: 2002, the CDR3-L consists of SEQ ID NO: 3002, the CDR1-H consists of SEQ ID NO: 4002, the CDR2- H consists of SEQ ID NO: 5002 and said CDR3-H consists of SEQ ID NO: 6002; or
The CDR1-L consists of SEQ ID NO: 1003, the CDR2-L consists of SEQ ID NO: 2003, the CDR3-L consists of SEQ ID NO: 3003, the CDR1-H consists of SEQ ID NO: 4003, and the CDR2 -H consists of SEQ ID NO:5003 and said CDR3-H consists of SEQ ID NO:6003; or
said CDR1-L consists of SEQ ID NO: 1004, said CDR2-L consists of SEQ ID NO: 2004, said CDR3-L consists of SEQ ID NO: 3004, said CDR1-H consists of SEQ ID NO: 4004, said CDR2 -H consists of SEQ ID NO:5004 and said CDR3-H consists of SEQ ID NO:6004; or
The CDR1-L consists of SEQ ID NO: 1005, the CDR2-L consists of SEQ ID NO: 2005, the CDR3-L consists of SEQ ID NO: 3005, the CDR1-H consists of SEQ ID NO: 4005, and the CDR2 -H consists of SEQ ID NO: 5005 and said CDR3-H consists of SEQ ID NO: 6005; or
said CDR1-L consists of SEQ ID NO: 1006, said CDR2-L consists of SEQ ID NO: 2006, said CDR3-L consists of SEQ ID NO: 3006, said CDR1-H consists of SEQ ID NO: 4006, said CDR2 -H consists of SEQ ID NO:5006 and said CDR3-H consists of SEQ ID NO:6006; or
The CDR1-L consists of SEQ ID NO: 1007, the CDR2-L consists of SEQ ID NO: 2007, the CDR3-L consists of SEQ ID NO: 3007, the CDR1-H consists of SEQ ID NO: 4007, and the CDR2 -H consists of SEQ ID NO:5007 and said CDR3-H consists of SEQ ID NO:6007; or
said CDR1-L consists of SEQ ID NO: 1008, said CDR2-L consists of SEQ ID NO: 2008, said CDR3-L consists of SEQ ID NO: 3008, said CDR1-H consists of SEQ ID NO: 4008, said CDR2 -H consists of SEQ ID NO: 5008 and said CDR3-H consists of SEQ ID NO: 6008; or
The CDR1-L consists of SEQ ID NO: 1009, the CDR2-L consists of SEQ ID NO: 2009, the CDR3-L consists of SEQ ID NO: 3009, the CDR1-H consists of SEQ ID NO: 4009, and the CDR2 -H consists of SEQ ID NO:5009 and said CDR3-H consists of SEQ ID NO:6009; or
The CDR1-L consists of SEQ ID NO: 1010, the CDR2-L consists of SEQ ID NO: 2010, the CDR3-L consists of SEQ ID NO: 3010, the CDR1-H consists of SEQ ID NO: 4010, and the CDR2 -H consists of SEQ ID NO: 5010 and said CDR3-H consists of SEQ ID NO: 6010; or
The CDR1-L consists of SEQ ID NO: 1011, the CDR2-L consists of SEQ ID NO: 2011, the CDR3-L consists of SEQ ID NO: 3011, the CDR1-H consists of SEQ ID NO: 4011, and the CDR2 -H consists of SEQ ID NO:5011 and said CDR3-H consists of SEQ ID NO:6011; or
said CDR1-L consists of SEQ ID NO: 1012, said CDR2-L consists of SEQ ID NO: 2012, said CDR3-L consists of SEQ ID NO: 3012, said CDR1-H consists of SEQ ID NO: 4012, said CDR2 -H consists of SEQ ID NO:5012 and said CDR3-H consists of SEQ ID NO:6012; or
said CDR1-L consists of SEQ ID NO: 1013, said CDR2-L consists of SEQ ID NO: 2013, said CDR3-L consists of SEQ ID NO: 3013, said CDR1-H consists of SEQ ID NO: 4013, said CDR2 -H consists of SEQ ID NO:5013 and said CDR3-H consists of SEQ ID NO:6013; or
said CDR1-L consists of SEQ ID NO: 1014, said CDR2-L consists of SEQ ID NO: 2014, said CDR3-L consists of SEQ ID NO: 3014, said CDR1-H consists of SEQ ID NO: 4014, said CDR2 -H consists of SEQ ID NO: 5014 and said CDR3-H consists of SEQ ID NO: 6014; or
said CDR1-L consists of SEQ ID NO: 1015, said CDR2-L consists of SEQ ID NO: 2015, said CDR3-L consists of SEQ ID NO: 3015, said CDR1-H consists of SEQ ID NO: 4015, said CDR2 -H consists of SEQ ID NO: 5015 and said CDR3-H consists of SEQ ID NO: 6015; or
said CDR1-L consists of SEQ ID NO: 1016, said CDR2-L consists of SEQ ID NO: 2016, said CDR3-L consists of SEQ ID NO: 3016, said CDR1-H consists of SEQ ID NO: 4016, said CDR2 -H consists of SEQ ID NO: 5016 and said CDR3-H consists of SEQ ID NO: 6016; or
said CDR1-L consists of SEQ ID NO: 1017, said CDR2-L consists of SEQ ID NO: 2017, said CDR3-L consists of SEQ ID NO: 3017, said CDR1-H consists of SEQ ID NO: 4017, said CDR2 -H consists of SEQ ID NO:5017 and said CDR3-H consists of SEQ ID NO:6017; or
said CDR1-L consists of SEQ ID NO: 1018, said CDR2-L consists of SEQ ID NO: 2018, said CDR3-L consists of SEQ ID NO: 3018, said CDR1-H consists of SEQ ID NO: 4018, said CDR2 -H consists of SEQ ID NO:5018 and said CDR3-H consists of SEQ ID NO:6018; or
The CDR1-L consists of SEQ ID NO: 1019, the CDR2-L consists of SEQ ID NO: 2019, the CDR3-L consists of SEQ ID NO: 3019, the CDR1-H consists of SEQ ID NO: 4019, and the CDR2 -H consists of SEQ ID NO: 5019 and said CDR3-H consists of SEQ ID NO: 6019; or
said CDR1-L consists of SEQ ID NO: 1020, said CDR2-L consists of SEQ ID NO: 2020, said CDR3-L consists of SEQ ID NO: 3020, said CDR1-H consists of SEQ ID NO: 4020, said CDR2 -H consists of SEQ ID NO: 5020 and said CDR3-H consists of SEQ ID NO: 6020; or
said CDR1-L consists of SEQ ID NO: 1021, said CDR2-L consists of SEQ ID NO: 2021, said CDR3-L consists of SEQ ID NO: 3021, said CDR1-H consists of SEQ ID NO: 4021, said CDR2 -H consists of SEQ ID NO: 5021 and said CDR3-H consists of SEQ ID NO: 6021; or
said CDR1-L consists of SEQ ID NO: 1022, said CDR2-L consists of SEQ ID NO: 2022, said CDR3-L consists of SEQ ID NO: 3022, said CDR1-H consists of SEQ ID NO: 4022, said CDR2 -H consists of SEQ ID NO:5022 and said CDR3-H consists of SEQ ID NO:6022; or
said CDR1-L consists of SEQ ID NO: 1023, said CDR2-L consists of SEQ ID NO: 2023, said CDR3-L consists of SEQ ID NO: 3023, said CDR1-H consists of SEQ ID NO: 4023, said CDR2 -H consists of SEQ ID NO:5023 and said CDR3-H consists of SEQ ID NO:6023; or
said CDR1-L consists of SEQ ID NO: 1024, said CDR2-L consists of SEQ ID NO: 2024, said CDR3-L consists of SEQ ID NO: 3024, said CDR1-H consists of SEQ ID NO: 4024, said CDR2 -H consists of SEQ ID NO:5024 and said CDR3-H consists of SEQ ID NO:6024; or
said CDR1-L consists of SEQ ID NO: 1025, said CDR2-L consists of SEQ ID NO: 2025, said CDR3-L consists of SEQ ID NO: 3025, said CDR1-H consists of SEQ ID NO: 4025, said CDR2 -H consists of SEQ ID NO:5025 and said CDR3-H consists of SEQ ID NO:6025; or
said CDR1-L consists of SEQ ID NO: 1026, said CDR2-L consists of SEQ ID NO: 2026, said CDR3-L consists of SEQ ID NO: 3026, said CDR1-H consists of SEQ ID NO: 4026, said CDR2 -H consists of SEQ ID NO: 5026 and said CDR3-H consists of SEQ ID NO: 6026; or
said CDR1-L consists of SEQ ID NO: 1027, said CDR2-L consists of SEQ ID NO: 2027, said CDR3-L consists of SEQ ID NO: 3027, said CDR1-H consists of SEQ ID NO: 4027, said CDR2 -H consists of SEQ ID NO:5027 and said CDR3-H consists of SEQ ID NO:6027; or
said CDR1-L consists of SEQ ID NO: 1028, said CDR2-L consists of SEQ ID NO: 2028, said CDR3-L consists of SEQ ID NO: 3028, said CDR1-H consists of SEQ ID NO: 4028, said CDR2 The ABP of item 1, wherein -H consists of SEQ ID NO:5028 and said CDR3-H consists of SEQ ID NO:6028.
(Item 5)
A variable light chain (V L ) comprising a sequence at least 97% identical to a sequence selected from SEQ ID NOs: 1-28, and a variable heavy chain comprising a sequence at least 97% identical to a sequence selected from SEQ ID NOs: 101-128 (V H ); or
A variable light chain (V L ) comprising a sequence at least 97% identical to a sequence selected from SEQ ID NOs:8000-8495 , and a variable heavy chain comprising a sequence at least 97% identical to a sequence selected from SEQ ID NOs:8496-8991 (V H ); or
a variable light chain (V L ) comprising a sequence that is at least 97% identical to the V L sequence of any one of the clones in the library deposited under ATCC Accession No. PTA-125512; A variable heavy chain ( VH ) comprising a sequence that is at least 97% identical to the VH sequence of any one of the clones in the library deposited below
The ABP of item 1, comprising
(Item 6)
The ABP of item 5, wherein said V L and said V H are a cognate pair.
(Item 7)
a variable light chain (V L ) comprising a sequence selected from SEQ ID NOs: 1-28, and a variable heavy chain (V H ) comprising a sequence selected from SEQ ID NOs : 101-128 ; or
a variable light chain (V L ) comprising a sequence selected from SEQ ID NOs:8000-8495 , and a variable heavy chain (V H ) comprising a sequence selected from SEQ ID NOs:8496-8991; or
A variable light chain (V L ) comprising the V L sequence of any one of the clones in the library deposited under ATCC Accession No. PTA-125512, and the library deposited under ATCC Accession No. PTA-125512 variable heavy chain (V H ) comprising the V H sequence of any one of the clones in
The ABP of item 1, comprising
(Item 8)
8. The ABP of item 7, wherein said V L and said V H are a cognate pair.
(Item 9)
9. ABP according to any of items 1 to 8, comprising a scFv or a full length monoclonal antibody.
(Item 10)
9. ABP according to any of items 1 to 8, comprising an immunoglobulin constant region.
(Item 11)
The ABP of any of the preceding items, which binds human CTLA-4 with a K D of less than 500 nM as measured by surface plasmon resonance .
(Item 12)
12. The ABP of item 11, which binds human CTLA-4 with a K D of less than 200 nM as measured by surface plasmon resonance .
(Item 13)
13. The ABP of item 12, which binds human CTLA-4 with a K D of less than 25 nM as measured by surface plasmon resonance .
(Item 14)
14. The ABP of any of items 1-13, which binds human CTLA-4 on the cell surface with a K D of less than 25 nM.
(Item 15)
A pharmaceutical composition comprising an ABP according to any one of items 1 to 14 and an excipient.
(Item 16)
A method of treating a disease comprising:
administering to a subject in need thereof an effective amount of the ABP of any one of items 1 to 14 or the pharmaceutical composition of item 15
A method, including
(Item 17)
17. The method of item 16, wherein said disease is selected from the group consisting of cancer, AIDS, Alzheimer's disease and viral or bacterial infections.
(Item 18)
18. The method of any of items 16-17, further comprising administering to said subject one or more additional therapeutic agents.
(Item 19)
19. The method of item 18, wherein said additional therapeutic agent is selected from CTLA-4 inhibitors, TIGIT inhibitors, chemotherapeutic agents, immunostimulatory agents, radiation, cytokines, polynucleotides encoding cytokines, and combinations thereof. Method.
(Item 20)
An isolated polynucleotide encoding the ABP of any of items 1-10.
(Item 21)
A vector comprising the isolated polynucleotide of item 20.
(Item 22)
A host cell comprising the isolated polynucleotide of item 20 or the vector of item 21.
(Item 23)
A method of producing an isolated antigen binding protein (ABP) that specifically binds to human CTLA-4, comprising:
expressing said ABP in the host cell of item 22 and isolating said ABP
method including.
6. Brief description of the drawing
Claims (17)
(a)配列番号1014、1007、1010、1012、1013、1002、1001、1003~1006、1008~1009、1011、および1015~1028から選択される配列を有するCDR1-L、配列番号2014、2007、2010、2012、2013、2002、2001、2003~2006、2008~2009、2011、および2015~2028から選択される配列を有するCDR2-L、配列番号3014、3007、3010、3012、3013、3002、3001、3003~3006、3008~3009、3011、および3015~3028から選択される配列を有するCDR3-L、配列番号4014、4007、4010、4012、4013、4002、4001、4003~4006、4008~4009、4011、および4015~4028から選択される配列を有するCDR1-H、配列番号5014、5007、5010、5012、5013、5002、5001、5003~5006、5008~5009、5011、および5015~5028から選択される配列を有するCDR2-H、ならびに配列番号6014、6007、6010、6012、6013、6002、6001、6003~6006、6008~6009、6011、および6015~6028から選択される配列を有するCDR3-H;または
(b)配列番号8992~9487から選択される配列を有するCDR1-L、配列番号9488~9983から選択される配列を有するCDR2-L、配列番号9984~10479から選択される配列を有するCDR3-L、配列番号10480~10975から選択される配列を有するCDR1-H、配列番号10976~11471から選択される配列を有するCDR2-H、ならびに配列番号11472~11967から選択される配列を有するCDR3-H;または
(c)ATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのCDR1-Lから選択される配列を有するCDR1-L、ATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのCDR2-Lから選択される配列を有するCDR2-L、ATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのCDR3-Lの配列を有するCDR3-L、ATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのCDR1-Hから選択される配列を有するCDR1-H、ATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのCDR2-Hから選択される配列を有するCDR2-H、ならびにATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのCDR3-Hの配列を有するCDR3-H
を含む、単離された抗原結合タンパク質(ABP)。 An isolated antigen binding protein (ABP) that specifically binds to human cytotoxic T lymphocyte-associated protein 4 (CTLA-4), comprising:
(a) CDR1-L having a sequence selected from SEQ ID NOs: 1014, 1007, 1010, 1012, 1013, 1002, 1001, 1003-1006, 1008-1009, 1011, and 1015-1028, SEQ ID NOs: 2014, 2007; CDR2-L having a sequence selected from 2010, 2012, 2013, 2002, 2001, 2003-2006, 2008-2009, 2011, and 2015-2028 , SEQ ID NOs: 3014, 3007, 3010, 3012, 3013, 3002, 3001 , 3003-3006, 3008-3009, 3011, and 3015-3028 ; 4011, and CDR1-H having a sequence selected from 4015-4028, selected from SEQ ID NOS: 5014, 5007, 5010, 5012, 5013, 5002, 5001, 5003-5006, 5008-5009, 5011, and 5015-5028 and CDR3-H having a sequence selected from SEQ ID NOs: 6014, 6007, 6010, 6012, 6013, 6002, 6001, 6003-6006, 6008-6009, 6011, and 6015-6028 ; or (b) CDR1-L having a sequence selected from SEQ ID NOs:8992-9487, CDR2-L having a sequence selected from SEQ ID NOs:9488-9983, CDR3- having a sequence selected from SEQ ID NOs:9984-10479 L, CDR1-H with sequences selected from SEQ ID NOs: 10480-10975, CDR2-H with sequences selected from SEQ ID NOs: 10976-11471, and CDR3-H with sequences selected from SEQ ID NOs: 11472-11967 or (c) a CDR1-L having a sequence selected from the CDR1-L of any one of the clones in the library deposited under ATCC Accession No. PTA-125512, under ATCC Accession No. PTA-125512. a CDR2-L having a sequence selected from the CDR2-L of any one of the clones in the deposited library; any one of the clones in the library deposited under ATCC Accession No. PTA-125512; CDR3-L having the sequence of CDR3-L, CDR1-H having a sequence selected from the CDR1-H of any one of the clones in the library deposited under ATCC Accession No. PTA-125512, ATCC Accession No. CDR2-H having a sequence selected from the CDR2-H of any one of the clones in the library deposited under PTA-125512, as well as in the library deposited under ATCC Accession No. PTA-125512 CDR3- H with the sequence of CDR3 - H of any one of the clones
An isolated antigen binding protein (ABP) comprising:
前記CDR1-Lが、配列番号1014からなり、前記CDR2-Lが、配列番号2014からなり、前記CDR3-Lが、配列番号3014からなり、前記CDR1-Hが、配列番号4014からなり、前記CDR2-Hが、配列番号5014からなり、前記CDR3-Hが、配列番号6014からなるか;または
前記CDR1-Lが、配列番号1007からなり、前記CDR2-Lが、配列番号2007からなり、前記CDR3-Lが、配列番号3007からなり、前記CDR1-Hが、配列番号4007からなり、前記CDR2-Hが、配列番号5007からなり、前記CDR3-Hが、配列番号6007からなるか;または
前記CDR1-Lが、配列番号1010からなり、前記CDR2-Lが、配列番号2010からなり、前記CDR3-Lが、配列番号3010からなり、前記CDR1-Hが、配列番号4010からなり、前記CDR2-Hが、配列番号5010からなり、前記CDR3-Hが、配列番号6010からなるか;または
前記CDR1-Lが、配列番号1012からなり、前記CDR2-Lが、配列番号2012からなり、前記CDR3-Lが、配列番号3012からなり、前記CDR1-Hが、配列番号4012からなり、前記CDR2-Hが、配列番号5012からなり、前記CDR3-Hが、配列番号6012からなるか;または
前記CDR1-Lが、配列番号1013からなり、前記CDR2-Lが、配列番号2013からなり、前記CDR3-Lが、配列番号3013からなり、前記CDR1-Hが、配列番号4013からなり、前記CDR2-Hが、配列番号5013からなり、前記CDR3-Hが、配列番号6013からなるか;または
前記CDR1-Lが、配列番号1002からなり、CDR2-Lが、配列番号2002からなり、前記CDR3-Lが、配列番号3002からなり、前記CDR1-Hが、配列番号4002からなり、前記CDR2-Hが、配列番号5002からなり、前記CDR3-Hが、配列番号6002からなるか;または
前記CDR1-Lが、配列番号1001からなり、前記CDR2-Lが、配列番号2001からなり、前記CDR3-Lが、配列番号3001からなり、前記CDR1-Hが、配列番号4001からなり、前記CDR2-Hが、配列番号5001からなり、前記CDR3-Hが、配列番号6001からなるか;または
前記CDR1-Lが、配列番号1003からなり、前記CDR2-Lが、配列番号2003からなり、前記CDR3-Lが、配列番号3003からなり、前記CDR1-Hが、配列番号4003からなり、前記CDR2-Hが、配列番号5003からなり、前記CDR3-Hが、配列番号6003からなるか;または
前記CDR1-Lが、配列番号1004からなり、前記CDR2-Lが、配列番号2004からなり、前記CDR3-Lが、配列番号3004からなり、前記CDR1-Hが、配列番号4004からなり、前記CDR2-Hが、配列番号5004からなり、前記CDR3-Hが、配列番号6004からなるか;または
前記CDR1-Lが、配列番号1005からなり、前記CDR2-Lが、配列番号2005からなり、前記CDR3-Lが、配列番号3005からなり、前記CDR1-Hが、配列番号4005からなり、前記CDR2-Hが、配列番号5005からなり、前記CDR3-Hが、配列番号6005からなるか;または
前記CDR1-Lが、配列番号1006からなり、前記CDR2-Lが、配列番号2006からなり、前記CDR3-Lが、配列番号3006からなり、前記CDR1-Hが、配列番号4006からなり、前記CDR2-Hが、配列番号5006からなり、前記CDR3-Hが、配列番号6006からなるか;または
前記CDR1-Lが、配列番号1008からなり、前記CDR2-Lが、配列番号2008からなり、前記CDR3-Lが、配列番号3008からなり、前記CDR1-Hが、配列番号4008からなり、前記CDR2-Hが、配列番号5008からなり、前記CDR3-Hが、配列番号6008からなるか;または
前記CDR1-Lが、配列番号1009からなり、前記CDR2-Lが、配列番号2009からなり、前記CDR3-Lが、配列番号3009からなり、前記CDR1-Hが、配列番号4009からなり、前記CDR2-Hが、配列番号5009からなり、前記CDR3-Hが、配列番号6009からなるか;または
前記CDR1-Lが、配列番号1011からなり、前記CDR2-Lが、配列番号2011からなり、前記CDR3-Lが、配列番号3011からなり、前記CDR1-Hが、配列番号4011からなり、前記CDR2-Hが、配列番号5011からなり、前記CDR3-Hが、配列番号6011からなるか;または
前記CDR1-Lが、配列番号1015からなり、前記CDR2-Lが、配列番号2015からなり、前記CDR3-Lが、配列番号3015からなり、前記CDR1-Hが、配列番号4015からなり、前記CDR2-Hが、配列番号5015からなり、前記CDR3-Hが、配列番号6015からなるか;または
前記CDR1-Lが、配列番号1016からなり、前記CDR2-Lが、配列番号2016からなり、前記CDR3-Lが、配列番号3016からなり、前記CDR1-Hが、配列番号4016からなり、前記CDR2-Hが、配列番号5016からなり、前記CDR3-Hが、配列番号6016からなるか;または
前記CDR1-Lが、配列番号1017からなり、前記CDR2-Lが、配列番号2017からなり、前記CDR3-Lが、配列番号3017からなり、前記CDR1-Hが、配列番号4017からなり、前記CDR2-Hが、配列番号5017からなり、前記CDR3-Hが、配列番号6017からなるか;または
前記CDR1-Lが、配列番号1018からなり、前記CDR2-Lが、配列番号2018からなり、前記CDR3-Lが、配列番号3018からなり、前記CDR1-Hが、配列番号4018からなり、前記CDR2-Hが、配列番号5018からなり、前記CDR3-Hが、配列番号6018からなるか;または
前記CDR1-Lが、配列番号1019からなり、前記CDR2-Lが、配列番号2019からなり、前記CDR3-Lが、配列番号3019からなり、前記CDR1-Hが、配列番号4019からなり、前記CDR2-Hが、配列番号5019からなり、前記CDR3-Hが、配列番号6019からなるか;または
前記CDR1-Lが、配列番号1020からなり、前記CDR2-Lが、配列番号2020からなり、前記CDR3-Lが、配列番号3020からなり、前記CDR1-Hが、配列番号4020からなり、前記CDR2-Hが、配列番号5020からなり、前記CDR3-Hが、配列番号6020からなるか;または
前記CDR1-Lが、配列番号1021からなり、前記CDR2-Lが、配列番号2021からなり、前記CDR3-Lが、配列番号3021からなり、前記CDR1-Hが、配列番号4021からなり、前記CDR2-Hが、配列番号5021からなり、前記CDR3-Hが、配列番号6021からなるか;または
前記CDR1-Lが、配列番号1022からなり、前記CDR2-Lが、配列番号2022からなり、前記CDR3-Lが、配列番号3022からなり、前記CDR1-Hが、配列番号4022からなり、前記CDR2-Hが、配列番号5022からなり、前記CDR3-Hが、配列番号6022からなるか;または
前記CDR1-Lが、配列番号1023からなり、前記CDR2-Lが、配列番号2023からなり、前記CDR3-Lが、配列番号3023からなり、前記CDR1-Hが、配列番号4023からなり、前記CDR2-Hが、配列番号5023からなり、前記CDR3-Hが、配列番号6023からなるか;または
前記CDR1-Lが、配列番号1024からなり、前記CDR2-Lが、配列番号2024からなり、前記CDR3-Lが、配列番号3024からなり、前記CDR1-Hが、配列番号4024からなり、前記CDR2-Hが、配列番号5024からなり、前記CDR3-Hが、配列番号6024からなるか;または
前記CDR1-Lが、配列番号1025からなり、前記CDR2-Lが、配列番号2025からなり、前記CDR3-Lが、配列番号3025からなり、前記CDR1-Hが、配列番号4025からなり、前記CDR2-Hが、配列番号5025からなり、前記CDR3-Hが、配列番号6025からなるか;または
前記CDR1-Lが、配列番号1026からなり、前記CDR2-Lが、配列番号2026からなり、前記CDR3-Lが、配列番号3026からなり、前記CDR1-Hが、配列番号4026からなり、前記CDR2-Hが、配列番号5026からなり、前記CDR3-Hが、配列番号6026からなるか;または
前記CDR1-Lが、配列番号1027からなり、前記CDR2-Lが、配列番号2027からなり、前記CDR3-Lが、配列番号3027からなり、前記CDR1-Hが、配列番号4027からなり、前記CDR2-Hが、配列番号5027からなり、前記CDR3-Hが、配列番号6027からなるか;または
前記CDR1-Lが、配列番号1028からなり、前記CDR2-Lが、配列番号2028からなり、前記CDR3-Lが、配列番号3028からなり、前記CDR1-Hが、配列番号4028からなり、前記CDR2-Hが、配列番号5028からなり、前記CDR3-Hが、配列番号6028からなる、請求項1に記載のABP。 including CDR1-L, CDR2-L, CDR3-L, CDR1-H, CDR2-H and CDR3-H;
said CDR1-L consists of SEQ ID NO: 1014, said CDR2-L consists of SEQ ID NO: 2014, said CDR3-L consists of SEQ ID NO: 3014, said CDR1-H consists of SEQ ID NO: 4014, said CDR2 -H consists of SEQ ID NO: 5014 and said CDR3-H consists of SEQ ID NO: 6014; or
The CDR1-L consists of SEQ ID NO: 1007, the CDR2-L consists of SEQ ID NO: 2007, the CDR3-L consists of SEQ ID NO: 3007, the CDR1-H consists of SEQ ID NO: 4007, and the CDR2 -H consists of SEQ ID NO:5007 and said CDR3-H consists of SEQ ID NO:6007; or
The CDR1-L consists of SEQ ID NO: 1010, the CDR2-L consists of SEQ ID NO: 2010, the CDR3-L consists of SEQ ID NO: 3010, the CDR1-H consists of SEQ ID NO: 4010, and the CDR2 -H consists of SEQ ID NO: 5010 and said CDR3-H consists of SEQ ID NO: 6010; or
said CDR1-L consists of SEQ ID NO: 1012, said CDR2-L consists of SEQ ID NO: 2012, said CDR3-L consists of SEQ ID NO: 3012, said CDR1-H consists of SEQ ID NO: 4012, said CDR2 -H consists of SEQ ID NO:5012 and said CDR3-H consists of SEQ ID NO:6012; or
said CDR1-L consists of SEQ ID NO: 1013, said CDR2-L consists of SEQ ID NO: 2013, said CDR3-L consists of SEQ ID NO: 3013, said CDR1-H consists of SEQ ID NO: 4013, said CDR2 -H consists of SEQ ID NO:5013 and said CDR3-H consists of SEQ ID NO:6013; or
The CDR1-L consists of SEQ ID NO: 1002, the CDR2-L consists of SEQ ID NO: 2002, the CDR3-L consists of SEQ ID NO: 3002, the CDR1-H consists of SEQ ID NO: 4002, the CDR2- H consists of SEQ ID NO: 5002 and said CDR3-H consists of SEQ ID NO: 6002; or
The CDR1-L consists of SEQ ID NO: 1001, the CDR2-L consists of SEQ ID NO: 2001, the CDR3-L consists of SEQ ID NO: 3001, the CDR1-H consists of SEQ ID NO: 4001, and the CDR2 -H consists of SEQ ID NO:5001 and said CDR3-H consists of SEQ ID NO:6001; or
The CDR1-L consists of SEQ ID NO: 1003, the CDR2-L consists of SEQ ID NO: 2003, the CDR3-L consists of SEQ ID NO: 3003, the CDR1-H consists of SEQ ID NO: 4003, and the CDR2 -H consists of SEQ ID NO: 5003 and said CDR3-H consists of SEQ ID NO: 6003; or said CDR1-L consists of SEQ ID NO: 1004 and said CDR2-L consists of SEQ ID NO: 2004 and said CDR3 -L consists of SEQ ID NO:3004, said CDR1-H consists of SEQ ID NO:4004, said CDR2-H consists of SEQ ID NO:5004, and said CDR3-H consists of SEQ ID NO:6004; or said CDR1 -L consists of SEQ ID NO: 1005, said CDR2-L consists of SEQ ID NO: 2005, said CDR3-L consists of SEQ ID NO: 3005, said CDR1-H consists of SEQ ID NO: 4005, said CDR2-H consists of SEQ ID NO: 5005 and said CDR3-H consists of SEQ ID NO: 6005; or said CDR1-L consists of SEQ ID NO: 1006 and said CDR2-L consists of SEQ ID NO: 2006 and said CDR3-L consists of SEQ ID NO: 3006, said CDR1-H consists of SEQ ID NO: 4006, said CDR2-H consists of SEQ ID NO: 5006, and said CDR3-H consists of SEQ ID NO: 6006; or
said CDR1-L consists of SEQ ID NO: 1008, said CDR2-L consists of SEQ ID NO: 2008, said CDR3-L consists of SEQ ID NO: 3008, said CDR1-H consists of SEQ ID NO: 4008, said CDR2 -H consists of SEQ ID NO: 5008 and said CDR3-H consists of SEQ ID NO: 6008; or said CDR1-L consists of SEQ ID NO: 1009 and said CDR2-L consists of SEQ ID NO: 2009 and said CDR3 -L consists of SEQ ID NO:3009, said CDR1-H consists of SEQ ID NO:4009, said CDR2-H consists of SEQ ID NO:5009, and said CDR3-H consists of SEQ ID NO:6009; or
The CDR1-L consists of SEQ ID NO: 1011, the CDR2-L consists of SEQ ID NO: 2011, the CDR3-L consists of SEQ ID NO: 3011, the CDR1-H consists of SEQ ID NO: 4011, and the CDR2 -H consists of SEQ ID NO:5011 and said CDR3-H consists of SEQ ID NO:6011; or
said CDR1-L consists of SEQ ID NO: 1015, said CDR2-L consists of SEQ ID NO: 2015, said CDR3-L consists of SEQ ID NO: 3015, said CDR1-H consists of SEQ ID NO: 4015, said CDR2 -H consists of SEQ ID NO: 5015 and said CDR3-H consists of SEQ ID NO: 6015; or said CDR1-L consists of SEQ ID NO: 1016 and said CDR2-L consists of SEQ ID NO: 2016 and said CDR3 -L consists of SEQ ID NO:3016, said CDR1-H consists of SEQ ID NO:4016, said CDR2-H consists of SEQ ID NO:5016, and said CDR3-H consists of SEQ ID NO:6016; or said CDR1 -L consists of SEQ ID NO: 1017, said CDR2-L consists of SEQ ID NO: 2017, said CDR3-L consists of SEQ ID NO: 3017, said CDR1-H consists of SEQ ID NO: 4017, said CDR2-H consists of SEQ ID NO: 5017 and said CDR3-H consists of SEQ ID NO: 6017; or said CDR1-L consists of SEQ ID NO: 1018 and said CDR2-L consists of SEQ ID NO: 2018 and said CDR3-L consists of SEQ ID NO: 3018, said CDR1-H consists of SEQ ID NO: 4018, said CDR2-H consists of SEQ ID NO: 5018, and said CDR3-H consists of SEQ ID NO: 6018; or said CDR1-L consists of SEQ ID NO: 1019, said CDR2-L consists of SEQ ID NO: 2019, said CDR3-L consists of SEQ ID NO: 3019, said CDR1-H consists of SEQ ID NO: 4019, said CDR2-H consists of consists of SEQ ID NO: 5019 and said CDR3-H consists of SEQ ID NO: 6019; or said CDR1-L consists of SEQ ID NO: 1020 and said CDR2-L consists of SEQ ID NO: 2020 and said CDR3-L consists of consists of SEQ ID NO: 3020, wherein said CDR1-H consists of SEQ ID NO: 4020, said CDR2-H consists of SEQ ID NO: 5020, and said CDR3-H consists of SEQ ID NO: 6020; consists of SEQ ID NO: 1021, said CDR2-L consists of SEQ ID NO: 2021, said CDR3-L consists of SEQ ID NO: 3021, said CDR1-H consists of SEQ ID NO: 4021, said CDR2-H consists of SEQ ID NO: 5021 and said CDR3-H consists of SEQ ID NO: 6021; or said CDR1-L consists of SEQ ID NO: 1022, said CDR2-L consists of SEQ ID NO: 2022, said CDR3-L consists of SEQ ID NO: 3022, said CDR1-H consists of SEQ ID NO: 4022, said CDR2 -H consists of SEQ ID NO: 5022 and said CDR3-H consists of SEQ ID NO: 6022; or said CDR1-L consists of SEQ ID NO: 1023 and said CDR2-L consists of SEQ ID NO: 2023 and said CDR3 -L consists of SEQ ID NO:3023, said CDR1-H consists of SEQ ID NO:4023, said CDR2-H consists of SEQ ID NO:5023, and said CDR3-H consists of SEQ ID NO:6023; or said CDR1 -L consists of SEQ ID NO: 1024, said CDR2-L consists of SEQ ID NO: 2024, said CDR3-L consists of SEQ ID NO: 3024, said CDR1-H consists of SEQ ID NO: 4024, said CDR2-H consists of SEQ ID NO: 5024 and said CDR3-H consists of SEQ ID NO: 6024; or said CDR1-L consists of SEQ ID NO: 1025 and said CDR2-L consists of SEQ ID NO: 2025 and said CDR3-L consists of SEQ ID NO: 3025, said CDR1-H consists of SEQ ID NO: 4025, said CDR2-H consists of SEQ ID NO: 5025, and said CDR3-H consists of SEQ ID NO: 6025; or said CDR1-L consists of SEQ ID NO: 1026, said CDR2-L consists of SEQ ID NO: 2026, said CDR3-L consists of SEQ ID NO: 3026, said CDR1-H consists of SEQ ID NO: 4026, said CDR2-H consists of consists of SEQ ID NO: 5026 and said CDR3-H consists of SEQ ID NO: 6026; or said CDR1-L consists of SEQ ID NO: 1027 and said CDR2-L consists of SEQ ID NO: 2027 and said CDR3-L consists of 3027, wherein said CDR1-H consists of SEQ ID NO: 4027, said CDR2-H consists of SEQ ID NO: 5027, and said CDR3-H consists of SEQ ID NO: 6027; or said CDR1-L consists of consists of SEQ ID NO: 1028, said CDR2-L consists of SEQ ID NO: 2028, said CDR3-L consists of SEQ ID NO: 3028, said CDRl-H consists of SEQ ID NO: 4028, said CDR2-H consists of SEQ ID NO: 5028, and said CDR3-H consists of SEQ ID NO: 6028. ABP according to 1.
配列番号8000~8495から選択される配列と少なくとも97%同一の配列を含む可変軽鎖(VL)、および配列番号8496~8991から選択される配列と少なくとも97%同一の配列を含む可変重鎖(VH);または
ATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのVL配列と少なくとも97%同一の配列を含む可変軽鎖(VL)、およびATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのVH配列と少なくとも97%同一の配列を含む可変重鎖(VH)
を含む、請求項1に記載のABP。 A variable light chain (V L ) comprising a sequence at least 97% identical to a sequence selected from SEQ ID NOs: 1-28, and a variable heavy chain comprising a sequence at least 97% identical to a sequence selected from SEQ ID NOs: 101-128 (V H ); or a variable light chain (V L ) comprising a sequence at least 97% identical to a sequence selected from SEQ ID NOs:8000-8495, and at least 97% identical to a sequence selected from SEQ ID NOs:8496-8991 a variable heavy chain (V H ) comprising the sequence; or a variable light chain (V L chain comprising a sequence at least 97% identical to the V L sequence of any one of the clones in the library deposited under ATCC Accession No. PTA-125512); V L ), and a variable heavy chain (V H ) comprising a sequence that is at least 97% identical to the V H sequence of any one of the clones in the library deposited under ATCC Accession No. PTA-125512
2. The ABP of claim 1, comprising
配列番号8000~8495から選択される配列を含む可変軽鎖(VL)、および配列番号8496~8991から選択される配列を含む可変重鎖(VH);または
ATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのVL配列を含む可変軽鎖(VL)、およびATCC受託番号PTA-125512の下で寄託されたライブラリー内のクローンのいずれか1つのVH配列を含む可変重鎖(VH)
を含む、請求項4に記載のABP。 a variable light chain (V L ) comprising a sequence selected from SEQ ID NOs: 1-28, and a variable heavy chain (V H ) comprising a sequence selected from SEQ ID NOs: 101-128; or selected from SEQ ID NOs: 8000-8495 and a variable heavy chain ( VH ) comprising a sequence selected from SEQ ID NOS: 8496-8991 ; or in the library deposited under ATCC Accession No. PTA-125512. A variable light chain (V L ) comprising the V L sequence of any one of the clones, and a variable heavy chain comprising the V H sequence of any one of the clones in the library deposited under ATCC Accession No. PTA-125512 ( VH )
5. The ABP of claim 4, comprising
請求項16に記載の宿主細胞において前記ABPを発現させること、および前記ABPを単離すること
を含む方法。
A method of producing an isolated antigen binding protein (ABP) that specifically binds to human CTLA-4, comprising:
17. A method comprising expressing said ABP in the host cell of claim 16 and isolating said ABP.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024014900A JP2024042072A (en) | 2018-12-27 | 2024-02-02 | Anti-CTLA-4 binding protein and methods of use thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862785659P | 2018-12-27 | 2018-12-27 | |
US62/785,659 | 2018-12-27 | ||
PCT/US2019/068820 WO2020140084A1 (en) | 2018-12-27 | 2019-12-27 | Anti-ctla-4 binding proteins and methods of use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024014900A Division JP2024042072A (en) | 2018-12-27 | 2024-02-02 | Anti-CTLA-4 binding protein and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022516071A JP2022516071A (en) | 2022-02-24 |
JPWO2020140084A5 true JPWO2020140084A5 (en) | 2023-01-10 |
Family
ID=71126610
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021537082A Pending JP2022516071A (en) | 2018-12-27 | 2019-12-27 | Anti-CTLA-4 binding protein and how to use it |
JP2024014900A Pending JP2024042072A (en) | 2018-12-27 | 2024-02-02 | Anti-CTLA-4 binding protein and methods of use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024014900A Pending JP2024042072A (en) | 2018-12-27 | 2024-02-02 | Anti-CTLA-4 binding protein and methods of use thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220064303A1 (en) |
EP (1) | EP3902821A4 (en) |
JP (2) | JP2022516071A (en) |
KR (1) | KR20210121045A (en) |
CN (1) | CN114008071A (en) |
AU (1) | AU2019413366A1 (en) |
BR (1) | BR112021012588A2 (en) |
CA (1) | CA3124961A1 (en) |
IL (1) | IL284156A (en) |
MX (1) | MX2021007848A (en) |
SG (1) | SG11202106764YA (en) |
WO (1) | WO2020140084A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018004988A (en) * | 2015-10-23 | 2018-11-09 | Merus Nv | Binding molecules that inhibit cancer growth. |
MX2022015948A (en) * | 2020-07-02 | 2023-04-05 | Gigagen Inc | Anti-ctla-4 binding proteins and methods of use thereof. |
EP4271484A1 (en) * | 2020-12-31 | 2023-11-08 | NovaRock Biotherapeutics, Ltd. | Antibodies to tnfr2 and uses thereof |
CA3220882A1 (en) * | 2021-07-02 | 2023-01-05 | David Scott Johnson | Anti-ctla-4 binding proteins and methods of use thereof |
WO2023108114A2 (en) * | 2021-12-10 | 2023-06-15 | Merck Sharp & Dohme Llc | Human mesothelin binders |
WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
WO2006029219A2 (en) * | 2004-09-08 | 2006-03-16 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
HUE043903T2 (en) * | 2012-12-03 | 2019-09-30 | Bristol Myers Squibb Co | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
DK3151921T3 (en) * | 2014-06-06 | 2019-12-02 | Bristol Myers Squibb Co | ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR CANCER FACTOR RECEPTORS (GITR) AND APPLICATIONS THEREOF |
AU2016219170B2 (en) * | 2015-02-13 | 2021-09-09 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CTLA4 |
KR102492532B1 (en) * | 2015-05-29 | 2023-01-30 | 아게누스 인코포레이티드 | Anti-CTLA-4 Antibodies and Methods of Using The Same |
MX2018006925A (en) * | 2015-12-15 | 2018-08-01 | Oncoimmune Inc | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof. |
SG10201603721TA (en) * | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
NL2017270B1 (en) * | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
WO2018209701A1 (en) * | 2017-05-19 | 2018-11-22 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4) |
-
2019
- 2019-12-27 CN CN201980092796.9A patent/CN114008071A/en active Pending
- 2019-12-27 EP EP19902920.8A patent/EP3902821A4/en active Pending
- 2019-12-27 US US17/418,776 patent/US20220064303A1/en active Pending
- 2019-12-27 WO PCT/US2019/068820 patent/WO2020140084A1/en unknown
- 2019-12-27 MX MX2021007848A patent/MX2021007848A/en unknown
- 2019-12-27 JP JP2021537082A patent/JP2022516071A/en active Pending
- 2019-12-27 SG SG11202106764YA patent/SG11202106764YA/en unknown
- 2019-12-27 AU AU2019413366A patent/AU2019413366A1/en active Pending
- 2019-12-27 CA CA3124961A patent/CA3124961A1/en active Pending
- 2019-12-27 BR BR112021012588-4A patent/BR112021012588A2/en unknown
- 2019-12-27 KR KR1020217023740A patent/KR20210121045A/en unknown
-
2021
- 2021-06-17 IL IL284156A patent/IL284156A/en unknown
-
2024
- 2024-02-02 JP JP2024014900A patent/JP2024042072A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019515646A5 (en) | ||
JP2020525032A5 (en) | ||
JP2019536430A5 (en) | ||
JP2022177090A5 (en) | ||
JP2018527919A5 (en) | ||
JP2013527761A5 (en) | ||
JP2018506961A5 (en) | ||
JP2017535257A5 (en) | ||
JP2020513791A5 (en) | ||
JP2013502913A5 (en) | ||
JP2019527194A5 (en) | ||
JP2010526028A5 (en) | ||
JP2016512551A5 (en) | ||
FI2155783T4 (en) | Cross-species-specific cd3-epsilon binding domain | |
JPWO2019129221A5 (en) | ||
WO2018117237A1 (en) | Anti-cd3 antibody, and molecule containing said antibody | |
JP2010509931A5 (en) | ||
JP2021508707A5 (en) | ||
JP2018510617A5 (en) | ||
JP2013519364A5 (en) | ||
JP2013509158A5 (en) | ||
JP2024016024A5 (en) | ||
JP2019521647A5 (en) | ||
JP2020522488A5 (en) | ||
JP2019505565A5 (en) |